
    
      Two part clinical trial designed to evaluate the efficacy of StaphVAX in adults on
      hemodialysis. Part A will evaluate the prevention of bacteremic infections in End Stage Renal
      Disease (ESRD) patients during the interval between 3 and 35 weeks after a single dose of
      StaphVAX. Part B of this study is designed to assess immunogenicity of a second [booster]
      dose of vaccine in patients completing Part A, and the cumulative (Part A + B) efficacy.
    
  